Pharmaceutical

NanoViricides Has Filed its Quarterly Report – NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the Horizon

SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum…

6 months ago

Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

– Findings demonstrate significant reduction in pain and opioid consumption through 96 hours versus active comparator – – Significantly greater…

6 months ago

Palisade Bio to Present at Digestive Disease Week (DDW) 2024

Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on…

6 months ago

G1 Therapeutics to Release Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on February 28, 2024

RESEARCH TRIANGLE PARK, N.C., Feb. 15, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will…

6 months ago

Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis

Designation Based on Pre-Clinical Data and Initial Clinical Data from the Company's MAvERIC-Pilot Phase II StudyThis is a Designated News…

6 months ago

Poolbeg Pharma PLC Announces Board Role Change and Launch of EIP

LONDON, UK / ACCESSWIRE / February 15, 2024 / Poolbeg Pharma (AIM:POLB, OTCQB:POLBF, "Poolbeg" or the "Company"), a biopharmaceutical company…

6 months ago

GE HealthCare Management to Present at Upcoming Investor Conferences

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC), is announcing today that its Vice President and Chief Financial Officer, Jay Saccaro, will be…

6 months ago

Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information

Conference Call Scheduled for Thursday, February 15 at 11:30 AM ESTNORTHVALE, NJ / ACCESSWIRE / February 14, 2024 / Elite…

6 months ago

Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter

Q2 2024 operating income of $2.4 millionQ2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 millionQ2 2024…

6 months ago

Skinvisible Announces Significant Progress in Licensee’s Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising…

6 months ago